The fiscal year 2025 concluded with a dramatic reshuffling at the pinnacle of the pharmaceutical industry’s sales leaderboard, signaling profound shifts in therapeutic priorities and market dynamics. While Merck’s oncology blockbuster Keytruda maintained its reign as the top-selling individual brand, generating an impressive $31.68 billion, the true narrative of the year was the meteoric ascent of GLP-1 receptor agonists. Eli Lilly’s tirzepatide (Mounjaro/Zepbound) and Novo Nordisk’s semaglutide (Ozempic/Wegovy) collectively surpassed Keytruda at the molecule level, heralding a new era dominated by metabolic and weight management therapies. This pivotal shift underscores the growing global health crisis of obesity and Type 2 diabetes and the pharmaceutical industry’s rapid response to these unmet medical needs.
Beyond the top three molecules, the FY2025 sales data, meticulously compiled from the primary filings of the Pharma 50 companies, revealed an industry characterized by robust growth in scaled specialty franchises. Drugs like Skyrizi, Rinvoq, Dupixent, Darzalex, Tremfya, and Kisqali all delivered substantial gains, reinforcing the continued expansion of immunologicals, which surged by 20.6%. This growth stands in stark contrast to an overall contraction observed in the broader pharma pipeline during the same period, suggesting a strategic consolidation of research and development efforts into high-impact, high-value therapeutic areas.
Keytruda’s Enduring Oncology Dominance
Merck’s Keytruda (pembrolizumab), an anti-PD-1 immunotherapy, once again demonstrated its formidable market presence, securing the number one spot for an individual brand with FY2025 sales of $31.68 billion. This figure represents a healthy 7.5% year-over-year (YoY) increase from its $29.482 billion in FY2024. Launched in 2014, Keytruda has consistently expanded its indications, becoming a cornerstone in the treatment of various cancers, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and renal cell carcinoma, among many others. Its broad utility and proven efficacy across multiple tumor types have cemented its status as a foundational therapy in modern oncology.
The sustained growth of Keytruda, despite its maturity in the market, is a testament to Merck’s aggressive lifecycle management strategies, including continuous clinical trials exploring new combinations and earlier lines of therapy. The drug’s established safety profile and widespread clinician adoption contribute significantly to its enduring commercial success. Merck has consistently invested heavily in R&D to expand Keytruda’s label, thereby extending its market exclusivity and maintaining its competitive edge against other immunotherapies. This strategic focus ensures that Keytruda remains a critical component of cancer treatment paradigms globally, driving significant revenue for the pharmaceutical giant.
The Unprecedented Ascent of GLP-1 Agonists
The most striking development in FY2025 was the explosive growth of GLP-1 receptor agonists, particularly Eli Lilly’s tirzepatide and Novo Nordisk’s semaglutide. These molecules, marketed under different brand names for diabetes and weight loss, collectively amassed sales that overshadowed Keytruda’s brand-level dominance.
Eli Lilly’s tirzepatide, marketed as Mounjaro for Type 2 diabetes and Zepbound for chronic weight management, generated a combined $36.507 billion in FY2025. Mounjaro alone posted $22.965 billion, nearly doubling its FY2024 sales of $11.540 billion with an astounding 99.0% YoY growth. Zepbound, approved later in FY2024 for obesity, surged to $13.542 billion, representing an astronomical 174.9% increase from its initial sales of $4.926 billion. This rapid uptake for Zepbound highlights the immense unmet need and market potential in the obesity sector.
Novo Nordisk’s semaglutide similarly demonstrated robust performance. Ozempic, primarily indicated for Type 2 diabetes, recorded $19.206 billion in FY2025, a 5.6% increase from $18.187 billion in FY2024. Its weight loss counterpart, Wegovy, achieved $11.955 billion, up 35.9% from $8.796 billion. When factoring in Rybelsus, Novo Nordisk’s oral semaglutide formulation, which contributed $3.339 billion (though experiencing a -5.2% decline in FY2025), the total semaglutide molecule sales reached $34.500 billion.
The combined molecule-level sales for tirzepatide ($36.507 billion) and semaglutide ($34.500 billion) underscore a seismic shift in the pharmaceutical landscape. These drugs, originally developed for Type 2 diabetes, have revolutionized the treatment of obesity, a condition linked to numerous comorbidities and a significant public health burden. The dual mechanism of tirzepatide (GIP and GLP-1 agonism) and the potent efficacy of semaglutide have garnered widespread attention from patients, healthcare providers, and investors alike.
The implications of this GLP-1 surge are far-reaching. It signals a paradigm shift in how metabolic diseases are managed, moving beyond traditional approaches to more effective pharmacological interventions. This trend is expected to drive continued innovation in the metabolic disease space, with numerous companies racing to develop next-generation weight loss and diabetes therapies. The immense demand has also presented manufacturing and supply chain challenges, which both Eli Lilly and Novo Nordisk are actively addressing to meet global patient needs. Inferred statements from both companies would likely emphasize their commitment to expanding production capacities and exploring further therapeutic applications for these groundbreaking molecules.
Robust Growth in Specialty Franchises and Immunologicals
Beyond the headline-grabbing competition at the very top, FY2025 was marked by the sustained, compounding growth of several established specialty franchises, particularly within the immunological therapeutic area. This sector, encompassing treatments for autoimmune diseases, inflammatory conditions, and certain cancers, collectively expanded by an impressive 20.6%, positioning it as one of the few large therapeutic buckets still experiencing significant growth amidst an overall contracting pharmaceutical pipeline.
Sanofi and Regeneron’s Dupixent (dupilumab) continued its upward trajectory, reaching $17.736 billion in FY2025 sales, a robust 20.2% increase from $14.754 billion. Dupixent’s success stems from its broad utility across multiple type 2 inflammatory conditions, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis, demonstrating the power of a single therapy addressing diverse patient populations.
AbbVie showcased two strong performers in this category. Skyrizi (risankizumab), indicated for psoriasis, psoriatic arthritis, and Crohn’s disease, delivered $17.562 billion, marking an exceptional 49.9% YoY growth from $11.718 billion. Its strong efficacy and dosing convenience have made it a preferred choice for clinicians. Rinvoq (upadacitinib), another AbbVie product, also demonstrated significant momentum, achieving $8.304 billion in sales, a 39.1% increase from $5.971 billion. Rinvoq targets various inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and ulcerative colitis.
Johnson & Johnson’s Darzalex (daratumumab), a treatment for multiple myeloma, grew to $14.351 billion, a solid 23.0% increase from $11.670 billion. Its continued success highlights the ongoing innovation and demand for advanced therapies in hematologic malignancies. J&J also saw Tremfya (guselkumab), for psoriasis and psoriatic arthritis, reach $5.155 billion, with an impressive 40.5% growth from $3.670 billion.
Novartis’s Kisqali (ribociclib), a CDK4/6 inhibitor for breast cancer, posted a remarkable 57.7% increase, reaching $4.783 billion from $3.033 billion. This growth underscores the critical need for effective targeted therapies in oncology and Kisqali’s growing market penetration in the competitive breast cancer landscape.
The sustained expansion of these specialty franchises indicates several underlying trends: the high efficacy and differentiated profiles of these drugs, their ability to address significant unmet medical needs in chronic and severe conditions, and effective market strategies by their manufacturers. These therapies often command premium pricing due to their innovative nature and improved patient outcomes, allowing companies to "compound" their sales rather than experience a plateau.
Notable Declines and the Impact of Patent Expiry
While many drugs celebrated growth, FY2025 also witnessed significant declines for several established blockbusters, primarily due to the impact of patent expirations, increased generic/biosimilar competition, and shifting market demands.
The most dramatic declines were seen in drugs facing biosimilar erosion. Johnson & Johnson’s Stelara (ustekinumab) experienced a sharp 41.3% drop, falling to $6.078 billion from $10.361 billion. AbbVie’s long-standing top-seller, Humira (adalimumab), continued its decline, plummeting by 49.5% to $4.540 billion from $8.993 billion, as biosimilar competition intensified in the U.S. market. Similarly, Bristol Myers Squibb’s Revlimid (lenalidomide) saw its sales nearly halved, down 48.9% to $2.951 billion from $5.773 billion, due to generic erosion. These declines illustrate the cyclical nature of the pharmaceutical industry, where innovative products eventually face a loss of exclusivity, opening the market to more affordable alternatives.
The tapering demand for COVID-19 related products also significantly impacted sales. Pfizer/BioNTech’s Comirnaty vaccine fell by 18.4% to $4.367 billion from $5.353 billion, while Pfizer’s antiviral Paxlovid suffered a steep 58.7% decline to $2.362 billion from $5.716 billion. These figures reflect the global transition from pandemic emergency response to endemic management, reducing the urgent need for large-scale procurement of these specific therapies.
Other notable declines include Merck’s Gardasil, the HPV vaccine, which saw a 39.0% decrease to $5.233 billion from $8.583 billion, likely due to fluctuations in vaccination campaigns and market saturation in some regions. Pfizer’s Ibrance (palbociclib) decreased by 5.6% to $4.122 billion, facing stiff competition from newer CDK4/6 inhibitors like Kisqali and Eli Lilly’s Verzenio. Bristol Myers Squibb’s Sprycel (dasatinib) also saw a significant drop of 61.7% to $493 million, possibly due to increased competition in the chronic myeloid leukemia space.
These declines underscore the continuous pressure on pharmaceutical companies to innovate and replenish their pipelines, as even the most successful drugs eventually face market challenges. The ability to manage patent cliffs and introduce next-generation therapies is crucial for sustained revenue growth.
Emerging and Rapidly Growing Therapies
Beyond the top sellers, FY2025 saw several newer drugs demonstrate impressive growth, indicating future revenue drivers and successful product launches across various therapeutic areas. Bristol Myers Squibb, in particular, showcased several rapidly ascending assets. Breyanzi (lisocabtagene maraleucel), a CAR T-cell therapy, experienced an 81.8% surge, reaching $1.358 billion from $747 million, highlighting the expanding role of advanced cell therapies in oncology. Camzyos (mavacamten), for obstructive hypertrophic cardiomyopathy, grew by an impressive 77.4% to $1.068 billion from $602 million, addressing a significant unmet need in cardiovascular disease. Other BMS drugs like Opdualag (nivolumab/relatlimab-rmbw) and Reblozyl (luspatercept) also posted strong growth of 27.7% and 31.2% respectively, signaling successful market penetration in oncology and hematology.
GSK also saw strong performance from its HIV portfolio. Cabenuva (cabotegravir/rilpivirine), a long-acting injectable for HIV treatment, grew by 38.4% to $1.847 billion, while Apretude (cabotegravir extended-release injectable suspension), for HIV pre-exposure prophylaxis (PrEP), surged by 57.1% to $578 million. These drugs represent significant advancements in HIV prevention and treatment, offering patients more convenient and effective options.
These rapidly growing drugs represent the next wave of blockbusters and highlight the industry’s focus on innovative, often specialized, treatments that address critical medical needs. Their success reflects strategic investments in R&D and effective commercialization efforts.
Broader Market Trends and Implications for the Future
The FY2025 Pharma 50 report provides a crucial snapshot of an industry in dynamic flux. The overarching narrative points to a strategic concentration of pharmaceutical innovation into high-value areas. The paradox of an overall contracting pipeline alongside robust growth in specific therapeutic categories, particularly immunology and metabolic diseases, suggests a more focused and efficient approach to drug discovery and development. Companies are increasingly prioritizing therapies with clear mechanisms of action, strong clinical efficacy, and the potential to address large, underserved patient populations or conditions with high disease burden.
The dominance of GLP-1 agonists signifies a long-term shift towards addressing lifestyle-related diseases with highly effective pharmacological interventions. This trend will likely reshape healthcare budgets, insurance coverage policies, and even food and wellness industries in the coming years. The high cost of these transformative therapies, alongside other specialty drugs, will continue to fuel debates around drug pricing, affordability, and access, impacting healthcare systems globally.
The sustained performance of immunological franchises underscores the continued investment in precision medicine and targeted therapies for autoimmune and inflammatory conditions. As these drugs become more refined, they offer improved outcomes and quality of life for patients with chronic diseases.
Conversely, the significant revenue erosion from patent cliffs and biosimilar/generic competition highlights the relentless pressure on pharmaceutical companies to continuously innovate. The ability to bring novel, differentiated therapies to market quickly and effectively is paramount for maintaining revenue streams and shareholder value. The decline of COVID-19 related drug sales also serves as a reminder of the transient nature of demand driven by public health emergencies.
In conclusion, FY2025 marked a pivotal year for the pharmaceutical industry, characterized by a landmark shift in the sales hierarchy driven by metabolic disease breakthroughs, enduring strength in specialty immunology and oncology, and the inevitable impact of patent expirations. The landscape is increasingly competitive, demanding strategic R&D investments, robust commercialization, and an unwavering focus on unmet patient needs to secure future growth.
Methodology Note: The ranking presented is derived from primary financial filings of the Pharma 50 companies for their fiscal year 2025. Sales figures are reported in millions of U.S. dollars ($M). Where a company reported sales in a currency other than USD (e.g., Euros, Danish Krone, Swiss Franc, British Pound), the original figure was converted to USD using the specified IRS exchange rate for accurate comparison.
Leave a Reply